Abstract
Functionalized magnetic nanoparticles followed two main directions in the field of biomedical applications: one direction is as image enhancing agents for magnetic resonance imaging (MRI) and the other is as drugdelivery devices for various biologically-active substances. A third field which just emerges in nanomedicine is the field of the so-called theranostic devices which combines in the same delivery vehicle both the therapeutic agent and the contrast substance. The advantages of using nanoparticles instead of larger carriers for delivery of both drug and image contrast enhancing agents will be highlighted throughout this review article. Despite the ever increasing number of articles reporting both in vitro and in vivo studies carried out on functionalized magnetic nanoparticles and envisaging their potential biomedical applications, only few formulations reached the phase of clinical trials and even fewer became marketed products. The perspectives in the field are open, since new drugs require new delivery devices and possibly new means of functionalization. At the same time, the field of nanomedicine also provides the opportunity to better exploit drugs that are already in clinical use by improving their bioavailability through appropriate nanoformulations.
Keywords: Magnetic nanoparticles, drug delivery, MRI, triggered release.
Current Pharmaceutical Design
Title:Functionalized magnetic nanoparticles for biomedical applications
Volume: 21 Issue: 42
Author(s): Dragoș Gudovan, Paul Cătălin Balaure, Dan Eduard Mihăiescu, Adrian Fudulu, Bogdan Purcăreanu and Mihai Radu
Affiliation:
Keywords: Magnetic nanoparticles, drug delivery, MRI, triggered release.
Abstract: Functionalized magnetic nanoparticles followed two main directions in the field of biomedical applications: one direction is as image enhancing agents for magnetic resonance imaging (MRI) and the other is as drugdelivery devices for various biologically-active substances. A third field which just emerges in nanomedicine is the field of the so-called theranostic devices which combines in the same delivery vehicle both the therapeutic agent and the contrast substance. The advantages of using nanoparticles instead of larger carriers for delivery of both drug and image contrast enhancing agents will be highlighted throughout this review article. Despite the ever increasing number of articles reporting both in vitro and in vivo studies carried out on functionalized magnetic nanoparticles and envisaging their potential biomedical applications, only few formulations reached the phase of clinical trials and even fewer became marketed products. The perspectives in the field are open, since new drugs require new delivery devices and possibly new means of functionalization. At the same time, the field of nanomedicine also provides the opportunity to better exploit drugs that are already in clinical use by improving their bioavailability through appropriate nanoformulations.
Export Options
About this article
Cite this article as:
Gudovan Dragoș, Balaure Cătălin Paul, Mihăiescu Eduard Dan, Fudulu Adrian, Purcăreanu Bogdan and Radu Mihai, Functionalized magnetic nanoparticles for biomedical applications, Current Pharmaceutical Design 2015; 21 (42) . https://dx.doi.org/10.2174/1381612821666151027151702
DOI https://dx.doi.org/10.2174/1381612821666151027151702 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Berberine Exerts Anti-cancer Activity by Modulating Adenosine Monophosphate- Activated Protein Kinase (AMPK) and the Phosphatidylinositol 3-Kinase/ Protein Kinase B (PI3K/AKT) Signaling Pathways
Current Pharmaceutical Design Down Regulated Expression of Claudin-1 and Claudin-5 and Up Regulation of β-Catenin: Association with Human Glioma Progression
CNS & Neurological Disorders - Drug Targets The Cytotoxic and Mechanistic Effects of Aaptamine on Hepatocellular Carcinoma
Anti-Cancer Agents in Medicinal Chemistry Hexokinase II: The Integration of Energy Metabolism and Control of Apoptosis
Current Medicinal Chemistry Non-Homologous DNA End Joining in Anticancer Therapy
Current Cancer Drug Targets Potential Anti-cancer Drugs Commonly Used for Other Indications
Current Cancer Drug Targets Trophoblast Invasion: A Possible Link Between Implantation Deficiencies and Preeclampsia
Current Women`s Health Reviews Aptamer-Targeted Oligonucleotide Theranostics: A Smarter Approach for Brain Delivery and the Treatment of Neurological Diseases
Current Topics in Medicinal Chemistry Role of Inflammatory Mediators in Angiogenesis
Current Drug Targets - Inflammation & Allergy Recent Development in the Fabrication of Collagen Scaffolds for Tissue Engineering Applications: A Review
Current Pharmaceutical Biotechnology Cytotoxic and Anticancer Activities of Isatin and Its Derivatives: A Comprehensive Review from 2000-2008
Anti-Cancer Agents in Medicinal Chemistry NOB1: A Potential Biomarker or Target in Cancer
Current Drug Targets Chemistry of Tumour Targeted T1 Based MRI Contrast Agents
Current Topics in Medicinal Chemistry The Human Glioma-Associated Oncogene Homolog 1 (GLI1) Family of Transcription Factors in Gene Regulation and Diseases
Current Genomics Cancer Nanotechnology - Prospects for Cancer Diagnostics and Therapy
Current Cancer Therapy Reviews Significance of High Levels of Endogenous Melatonin in Mammalian Cerebrospinal Fluid and in the Central Nervous System
Current Neuropharmacology IAPs as a Target for Anticancer Therapy
Current Cancer Drug Targets Pharmacological Inhibitors of NAD Biosynthesis as Potential An ticancer Agents
Recent Patents on Anti-Cancer Drug Discovery Modulation of Immuno-biome during Radio-sensitization of Tumors by Glycolytic Inhibitors
Current Medicinal Chemistry Pharmacological Modulation of Nitric Oxide Release: New Pharmacological Perspectives, Potential Benefits and Risks
Current Medicinal Chemistry